[Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].

In many medical institutes the treatment for advanced (not resectable or radical grade C) or recurrent gastric cancer seems to be based on a regional perspective or prognostic restriction, and rarely on large-scale clinical studies; instead the selection is based on effective cases reported in the literature or on own.s own. In the current situation, chemotherapy using new anti-cancer drugs since S-1 has actually appeared to improve the prognosis or to maintain better QOL.

[Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].

The purpose of the present multi-center collaborative study was to elucidate the efficacy of intraportal chemotherapy with the combination of 5-FU and MMC for the prevention of liver recurrence after resection for colorectal cancer. A total of 125 patients with Stage II, III, and IV colorectal cancer were enrolled in this study between June 1993 and December 1995. Of them, 45 patients were randomized to a portal group: 10 mg/body of mitomycin one shot portal infusion, before and after 500 mg/m2 of 5-FU per 24 h for 7 days portal infusion followed by administration of oral 5-FU.